Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

2001531 citationsJournal Articlebronze Open Access

Authors

James R. Berenson · Cedars-Sinai Medical Center

Lee S. Rosen · University of California, Los Angeles

Anthony Howell · The Christie Hospital

Lester Porter · St. Thomas Medical Group

Robert E. Coleman · Yorkshire Cancer Research

Walter Morley · American Medical Research

Robert Dreicer

Abstract

A 5-minute infusion of 2.0-4.0 mg zoledronic acid was at least as effective as a 2-hour 90-mg pamidronate infusion in treatment of osteolytic metastases. A 0.4-mg dose of zoledronic acid was significantly less effective. Both zoledronic acid and pamidronate were well tolerated.

Topics & Keywords

Bone health and treatments Radiopharmaceutical Chemistry and Applications Prostate Cancer Treatment and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 91, Issue 7, pp. 1191-1200

DOI: 10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0

Field-Weighted Citation Impact: 17.12

Command Palette